Drugs / ET-26
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06176716 | Dec 2023 → Mar 2024 | liver disorder | Ahon Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT06822166 | Dec 2023 → Jan 2024 | — | Ahon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06203431 | Oct 2023 → Apr 2024 | — | Ahon Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ET-26 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06822166 ↗ |